Chris Behrenbruch

Chris is a serial entrepreneur with a diverse background in commercializing products in the medtech and biotech space. Chris has been involved in starting or financing over 20 innovative companies, mostly from technologies transferred out of the university setting.
He is currently the CEO of Telix Pharmaceuticals Limited, a Melbourne-based biotechnology company and Director of Factor Therapeutics Limited (ASX: FTT). Previously, Chris was CEO of ImaginAb, Inc. a clinical stage antibody engineering (a UCLA spin-out), Vice President at Siemens Healthcare following the acquisition of Mirada Solutions (Co-founder/CEO) and CTI Molecular Imaging (Sr. VP), where he was responsible for advanced medical imaging product development for clinical and drug discovery applications.
Chris is a Monash Alumnus (B.Eng). He has received a D.Phil (Ph.D) in Biomedical Engineering from the University of Oxford, an MBA jointly from NYU and the London School of Economics, and a JD from the University of Melbourne.

Our Sponsors